Drug Marketing

The Orphan Drug Act “unambiguously entitles” Eagle Pharmaceuticals a seven-year period of marketing exclusivity for a drug that treats leukemia and non-Hodgkin lymphoma, the U.S. Court of Appeals for the D.C. Circuit ruled.

WASHINGTON – The Orphan Drug Act “unambiguously entitles” Eagle Pharmaceuticals a seven-year period of marketing exclusivity for a drug that treats leukemia and non-Hodgkin lymphoma, the U.S. Court of Appeals for the D.C. Circuit ruled.

Categories / Appeals, Business, Government, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Drug Marketing

Subscribe to Closing Arguments

Additional Reads